Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Endometrial Neoplasms × spartalizumab × Clear all

Phase

Phase 1/2 2 Phase 1 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 NSCLC 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Advanced Solid Tumor 1

Interventions

Paclitaxel 3 Megestrol Acetate 3 Medroxyprogesterone Acetate 3 Letrozole 3 Carboplatin 3 Gonadotropin-Releasing Hormone 2 Cisplatin 2 spartalizumab 1 sintilimab 1 ricin A-GnRH conjugate 1 olaparib 1 niraparib 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 durvalumab 1 Tablets 1 Progestins 1 Progesterone 1 Observation 1 LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1 Drug Therapy 1 Cyproterone acetate, ethinyl estradiol drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡